| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/18/2002 | US6407137 Dopamine analog amide |
| 06/18/2002 | US6407117 Administering irinotecan hydrochloride and bicarbonate to maintain intestinal lumen alkalinity and prevent diarrhea; aids treatment |
| 06/18/2002 | US6407079 Inclusion compound etherified cyclodextrin; nontoxic, stability |
| 06/18/2002 | US6407057 Ovulation triggering drugs |
| 06/18/2002 | US6406894 Biodegradable polymer, disaccharide or oligosaccharide, crosslinking and coupling |
| 06/18/2002 | US6406885 Plant cell transformation vectors and dna code intimin |
| 06/18/2002 | US6406710 Protein occlusion for delivery of small molecules |
| 06/18/2002 | US6406708 Therapeutic compositions |
| 06/18/2002 | US6406693 Killing tumor vascular endothelial cells by treatment with antibodies and binding with antigens |
| 06/18/2002 | US6406679 Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells |
| 06/13/2002 | WO2002046419A2 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/13/2002 | WO2002046241A2 Polynuclear complex fe(iii) with pullulan oligomers, process of its obtaining, and pharmaceutical preparations on the basis of the complex |
| 06/13/2002 | WO2002046239A1 Thermoplastic and water soluble cellulose ether esters |
| 06/13/2002 | WO2002046232A2 Multimeric single-chain antibody with multiple antigen binding |
| 06/13/2002 | WO2002046147A2 Perturbed membrane-binding compounds |
| 06/13/2002 | WO2002045754A2 Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| 06/13/2002 | WO2002045753A2 Oral extended release formulation of gepirone |
| 06/13/2002 | WO2002045752A2 Dermal anti-inflammatory composition |
| 06/13/2002 | WO2002045746A2 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
| 06/13/2002 | WO2002045738A2 Vaccine composition containing transforming growth factor alpha |
| 06/13/2002 | WO2002045730A1 Antimonocytic activity of extracts of piper betel leaves |
| 06/13/2002 | WO2002045721A1 Noble gas complexes |
| 06/13/2002 | WO2002045714A1 Drug formulation having improved oral tolerability |
| 06/13/2002 | WO2002045713A2 Orally-bioavailable formulations of fentanyl and congeners thereof |
| 06/13/2002 | WO2002045709A1 Clear propofol compositions |
| 06/13/2002 | WO2002045707A2 Polynucleotide intercalator interceptors and inhibitors |
| 06/13/2002 | WO2002045701A2 Crystallization inhibition of drugs in transdermal drug delivery systems |
| 06/13/2002 | WO2002045699A2 Transdermal therapeutic system comprising the active ingredient oxybutynin |
| 06/13/2002 | WO2002045698A2 Silicone gel sheet for treatment of scar tissue |
| 06/13/2002 | WO2002045697A2 Composite material for counteracting edema |
| 06/13/2002 | WO2002045695A2 Hydrostatic delivery system for controlled delivery of agent |
| 06/13/2002 | WO2002045694A1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045693A1 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 06/13/2002 | WO2002045692A1 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045691A2 Laboratory scale milling process |
| 06/13/2002 | WO2002045689A1 Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof |
| 06/13/2002 | WO2002045688A2 Composition for treatment of inflammatory disorders |
| 06/13/2002 | WO2002045687A2 Topical alcoholic solution of a salicylic acid derivative and acemannan |
| 06/13/2002 | WO2002045686A2 Pharmaceutical paste comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045685A2 Cristallizable/non crystallizable polymer composites |
| 06/13/2002 | WO2002045684A2 Rapidly dispersing pharmaceutical composition comprising effervescent agents |
| 06/13/2002 | WO2002045683A2 Reversible gelling system for ocular drug delivery |
| 06/13/2002 | WO2002045682A1 Particulate inhalation carrier |
| 06/13/2002 | WO2002045681A2 Solid polyunsaturated fatty acid compositions |
| 06/13/2002 | WO2002045662A2 Anhydrous creams, lotions and gels |
| 06/13/2002 | WO2002009710A3 Paroxetine tablets and capsules |
| 06/13/2002 | WO2002007712A3 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 06/13/2002 | WO2002003962A3 Drug delivery system for poorly water soluble drugs |
| 06/13/2002 | WO2002002146A3 Dextrin-amphotericin conjugates and their methods of preparation |
| 06/13/2002 | WO2002000173A3 Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells |
| 06/13/2002 | WO2001095884A3 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 06/13/2002 | WO2001094547A3 Molecular delivery vehicle for delivery of selected compounds to targets |
| 06/13/2002 | WO2001093829A3 Powder compositions |
| 06/13/2002 | WO2001090159A3 Compositions and methods for delivery of a molecule into a cell |
| 06/13/2002 | WO2001085257A3 Opioid antagonist compositions and dosage forms |
| 06/13/2002 | WO2001082899A3 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| 06/13/2002 | WO2001078748A3 Immunomodulatory methods using carbohydrate antigens |
| 06/13/2002 | WO2001076577A3 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| 06/13/2002 | WO2001072277A3 Immunotherapeutic methods and compositions |
| 06/13/2002 | WO2001035942A3 Analgesic compositions containing buprenorphine |
| 06/13/2002 | WO2001028538A3 Laxative preparation containing l-arginine |
| 06/13/2002 | WO2001000199A9 Compounds obtained from salvia species having antiviral activity |
| 06/13/2002 | US20020073428 Downloading and transfer of audio or video data from video broadcasts |
| 06/13/2002 | US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant |
| 06/13/2002 | US20020072509 Methods for the treatment of a traumatic central nervous system injury |
| 06/13/2002 | US20020072506 Suited to thickening or structuring a water-immiscible liquid, for example, a phase in a cosmetic formulation, such as antiperspirant or deodorant formulations, eg water in oil emulsions and especially translucent ones |
| 06/13/2002 | US20020072480 Water-soluble, chlorhexidine-containing compositions and use thereof |
| 06/13/2002 | US20020072121 Composition for use in stable transfer on nucleotide sequences into cells |
| 06/13/2002 | US20020071874 Compositions containing therapeutically active components having enhanced solubility |
| 06/13/2002 | US20020071870 Particulates of a water-insoluble pharmaceutical having a solubility of less than 15 mg/ml in an aqueous carrier liquid, then microfluidizing said composition in the presence of at least 0.01% by weight of particulates of a dextrin. |
| 06/13/2002 | US20020071861 System for dermal or transdermal application containing an iota-carrageenan and process for its preparation |
| 06/13/2002 | US20020071857 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 06/13/2002 | US20020071855 Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers |
| 06/13/2002 | US20020071852 Products for topical applications comprising oil bodies |
| 06/13/2002 | US20020071846 Vaccines comprising oil bodies |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071841 Recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells; screening for malignant gliomas and meningiomas; treating glioblastoma multiforme and astrocytomas. |
| 06/13/2002 | US20020071837 Preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,OOO MW |
| 06/13/2002 | US20020071835 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 06/13/2002 | US20020071826 Targeted delivery system comprising at least one component-specific immunostimulating molecule bound to a platform. |
| 06/13/2002 | US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer. |
| 06/13/2002 | US20020071821 Therapeutic azo-compounds for drug delivery |
| 06/13/2002 | US20020071812 Contain 1,1,1,2,3,3,3-heptafluoropropane; especially with a betamimetic, an anticholinergic, a steroid, an antiallergic or a PAF-antagonist or a combination of such compounds. |
| 06/13/2002 | US20020071810 Container is provided with a non-metal interior surface so as to reduce chemical degradation |
| 06/13/2002 | US20020071809 Effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. |
| 06/13/2002 | DE10059825A1 Verwendung von kammförmigen Copolymeren auf Basis von Acryloyldimethyltaurinsäure in kosmetischen, pharmazeutischen und dermatologischen Mitteln Use of comb-shaped copolymers based on acryloyldimethyltaurine in cosmetic, pharmaceutical and dermatological compositions |
| 06/13/2002 | DE10059824A1 Elektrolythaltige kosmetische, pharmazeutische und dermatologische Mittel Electrolyte-containing cosmetic, pharmaceutical and dermatological compositions |
| 06/13/2002 | DE10059822A1 Saure kosmetische, pharmazeutische und dermatologische Mittel Acid cosmetic, pharmaceutical and dermatological compositions |
| 06/13/2002 | DE10059821A1 Tensidfreie kosmetische, dermatologische und pharmazeutische Mittel Surfactant-free cosmetic, dermatological and pharmaceutical agents |
| 06/13/2002 | DE10059819A1 Tensidhaltige kosmetische, dermatologische und pharmazeutische Mittel Surfactant-containing cosmetic, dermatological and pharmaceutical agents |
| 06/13/2002 | DE10059151A1 Magnetische Partikel zur Zielgerichteten Regionalen Therapie Magnetic particles for Targeted Therapy Regional |
| 06/13/2002 | CA2716959A1 Glp-1 fusion proteins |
| 06/13/2002 | CA2436692A1 Oral extended release formulation of gepirone |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2436574A1 Laboratory scale milling process |
| 06/13/2002 | CA2436570A1 Rapidly dispersing pharmaceutical composition comprising effervescent agents |
| 06/13/2002 | CA2432549A1 Clear propofol compositions |
| 06/13/2002 | CA2431306A1 Anhydrous creams, lotions and gels |
| 06/13/2002 | CA2430621A1 Vaccine composition containing transforming growth factor alpha |
| 06/13/2002 | CA2429727A1 Solid polyunsaturated fatty acid compositions |